Talia Technology develops, manufactures and sells proprietary ophthalmic imaging systems for early detection, diagnosis and follow-up of the major debilitating yet treatable back of the eye diseases.

Talia’s proprietary flagship product, the Retinal Thickness Analyzer (‘‘RTA’’), has received marketing clearance from the FDA and European Union and has been supported worldwide by more than 120 clinical studies, articles and publications by medical centers, clinics and opinion leaders.

The new RTA, launched at the end of 2001, allows diagnosis and monitoring of Glaucoma, Diabetic Retinopathy and AMD, major eye diseases that substantially impact more than 175 million people worldwide with visual impairment.

In 2005, through major technological breakthroughs, Talia designed and built a new RTA model, based on the RTA platform, offering a quick and easy Vision Wellness examination.

In 2006, Talia launched the VSL Analyzer, a stand-alone product used for assessing risk for stroke through analysis of retinal blood vessels. This might very well be the first step in a comprehensive solution to diagnosing various non-ophthalmic diseases through the eye.